Replies to post #687065 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Reprint:

I don’t know what the share price will do in the near future, but I know the better our news gets, the more achievements that occur and the closer we get to commercialization, automation and combinations, the more price per share pressure this stock undergoes from negative outside forces. Those of us that are still here, and I can’t speak for everyone, hope that DCVax-l and the entire platform will make it through to the other side. There are many reasons to believe it will, in particular the science and long term survival in monotherapy, monotherapy plus SOC, the apparent imminently chosen formula with poly-iclc, and future combinations with CIs and other immunotherapies.* Presently, it should start with monotherapy in rGBM and SOC + DCVax-l in nGBM. — flipper44

* Of course, add DCVax-Direct and hyperactivated dendritic cells to that mix as well.